BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Takeda Pharmaceutical Company readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Takeda Pharmaceutical Company's d
 rugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05456685-11140@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT05456
 685)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line 
 Treatment of Folate Receptor Alpha (FRα) Expressing\, Platinum-sensitive 
 Epithelial Ovarian Cancer\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5456685
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122687-2254@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:IBI363: Phase 2 readout est. (NCT07122687)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 C
 ombined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as N
 eoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07122687
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812078-11361@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK-360: Phase 2 readout est. (NCT06812078)
DESCRIPTION:TAK-360\, phase 2.\nStudy: A Study of TAK-360 in Adults With Id
 iopathic Hypersomnia\nEstimated primary completion: 30 November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tak-360#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06812078
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952699-11361@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK-360: Phase 2 readout est. (NCT06952699)
DESCRIPTION:TAK-360\, phase 2\, Narcolepsy.\nStudy: A Study of TAK-360 in A
 dults With Narcolepsy Without Cataplexy (NT2)\nEstimated primary completio
 n: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tak-360#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06952699
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363720-11363@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Orzeyful (Oveporexton): Phase 3 readout est. (NCT07363720)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 3\, Narcolepsy.\nStudy: A Trial 
 of TAK-861 for the Treatment of Narcolepsy With Cataplexy\nEstimated prima
 ry completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/oveporexton#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07363720
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797297-2254@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 2 readout est. (NCT06797297)
DESCRIPTION:IBI363\, phase 2.\nStudy: A Study to Evaluate the Efficacy and 
 Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Un
 resectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Ha
 d Not Previously Received Systemic Therapy\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibi
 363#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06797297
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402070-2254@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 2 readout est. (NCT07402070)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 a
 s Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cance
 r\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07402070
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365853-11140@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06365
 853)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study of Ocular Toxicity Evaluation and Mitigation During Treat
 ment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian
  Cancer With High Folate Receptor-Alpha Expression\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/mirvetuximab-soravtansine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06365853
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244263-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07244263)
DESCRIPTION:zasocitinib\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy of Zasocitinib in Adults With Hidradenitis Suppurativa\nEstimated prima
 ry completion: 5 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07244263
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973304-9608@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:teduglutide (Gattex): Phase 3 readout est. (NCT06973304)
DESCRIPTION:teduglutide (Gattex)\, phase 3\, Short Bowel Syndrome.\nStudy: 
 A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome\nEstima
 ted primary completion: 10 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teduglutide-gattex#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06973304
URL:https://assetmemo.bio/drug/teduglutide-gattex#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06233461-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:zasocitinib: Phase 2 readout est. (NCT06233461)
DESCRIPTION:zasocitinib\, phase 2.\nStudy: A Study on the Safety of TAK-279
  and Whether it Can Reduce Inflammation in the Bowel of Participants With 
 Moderately to Severely Active Crohn's Disease\nEstimated primary completio
 n: 17 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zasocitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06233461
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683003-10318@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Adzynma (Apadamtase alfa): Phase 3 readout est. (NCT04683003)
DESCRIPTION:Adzynma (Apadamtase alfa)\, phase 3.\nStudy: A Study of TAK-755
  in Participants With Congenital Thrombotic Thrombocytopenic Purpura\nEsti
 mated primary completion: 16 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/apadamtase-alfa#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04683003
URL:https://assetmemo.bio/drug/apadamtase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108283-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07108283)
DESCRIPTION:zasocitinib\, phase 2\, Vitiligo.\nStudy: A Study of Zasocitini
 b in Adults With Nonsegmental Vitiligo\nEstimated primary completion: 26 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zasocitini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 108283
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-11140@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 3 readout est. (NCT05445
 778)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 3\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as 
 Maintenance in Platinum-sensitive Epithelial Ovarian\, Fallopian Tube\, or
  Peritoneal Cancer\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671483-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671483)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologi
 c Medicines\nEstimated primary completion: 18 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06671483
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671496-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06671496)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been 
 Treated With Biologic Medicines\nEstimated primary completion: 18 May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zasocitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06671496
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752108-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07752108)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Study of Zasocitin
 ib in Adults With Non-pustular Palmoplantar Psoriasis\nEstimated primary c
 ompletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07752108
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06227910-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06227910)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Di
 sease\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06227910
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06786624-810@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06786624)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: Stud
 y to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatm
 ent in Participants With Major Depressive Disorder (MDD)\nEstimated primar
 y completion: July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/osavampator#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06786624
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911112-810@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06911112)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06911112
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963021-810@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Osavampator: Phase 3 readout est. (NCT06963021)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: NBI-
 1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as
  an Adjunctive Treatment in Participants With Major Depressive Disorder (M
 DD)\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osavampator#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963021
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04779320-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT04779320)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn
 's Disease (CD)\nEstimated primary completion: 13 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04779320
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03221036-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT03221036)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: E
 fficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerati
 ve Colitis\nEstimated primary completion: 24 September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03221036
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648030-10912@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:rusfertide: Phase 2 readout est. (NCT07648030)
DESCRIPTION:rusfertide\, phase 2\, Polycythemia Vera.\nStudy: A Study of Ru
 sfertide in Japanese Adults With Polycythemia Vera\nEstimated primary comp
 letion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rusfertide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07648030
URL:https://assetmemo.bio/drug/rusfertide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633301-11361@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271128
DTEND;VALUE=DATE:20271129
SUMMARY:TAK-360: Phase 2 readout est. (NCT07633301)
DESCRIPTION:TAK-360\, phase 2\, Narcolepsy.\nStudy: A Study of TAK-360 in A
 dults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)\nEstimated primar
 y completion: 28 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tak-360#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07633301
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06798012-11362@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:TAK-411: Phase 2 readout est. (NCT06798012)
DESCRIPTION:TAK-411\, phase 2.\nStudy: A Study of TAK-411 in Adults With Ch
 ronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)\nEstimated 
 primary completion: 2 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/tak-411#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06798012
URL:https://assetmemo.bio/drug/tak-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392450-10318@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Adzynma (Apadamtase alfa): Phase 2 readout est. (NCT07392450)
DESCRIPTION:Adzynma (Apadamtase alfa)\, phase 2\, Acute Ischemic Stroke.\nS
 tudy: A Study of TAK-755 in Adults With Acute Ischemic Stroke\nEstimated p
 rimary completion: 6 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/apadamtase-alfa#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07392450
URL:https://assetmemo.bio/drug/apadamtase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03934372-10794@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT03934372)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Chronic Myeloid Leukemia.\nSt
 udy: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent
  or Refractory Leukemias\, Lymphomas or Solid Tumors\nEstimated primary co
 mpletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03934372
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05037760-11364@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Elritercept: Phase 2 readout est. (NCT05037760)
DESCRIPTION:Elritercept\, phase 2.\nStudy: A Study of Elritercept Alone or 
 Together With Ruxolitinib in Adults With Myelofibrosis\nEstimated primary 
 completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/elritercept#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05037760
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05816382-11363@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Orzeyful (Oveporexton): Phase 2/3 readout est. (NCT05816382)
DESCRIPTION:Orzeyful (Oveporexton)\, phase 2/3\, Narcolepsy.\nStudy: A Stud
 y of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions\
 nEstimated primary completion: 28 February 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/oveporexton#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05816382
URL:https://assetmemo.bio/drug/oveporexton#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06722235-3188@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280316
DTEND;VALUE=DATE:20280317
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06722235)
DESCRIPTION:Mezagitamab\, phase 3.\nStudy: A Study of Mezagitamab in Adults
  With Chronic Primary Immune Thrombocytopenia\nEstimated primary completio
 n: 16 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mez
 agitamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06722235
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07403968-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:zasocitinib: Phase 2 readout est. (NCT07403968)
DESCRIPTION:zasocitinib\, phase 2.\nStudy: A Study of Zasocitinib (TAK-279)
  in Adults With Active Crohn's Disease\nEstimated primary completion: 30 M
 arch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zasocitini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 403968
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06076642-11365@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:TAK-881: Phase 3 readout est. (NCT06076642)
DESCRIPTION:TAK-881\, phase 3\, Primary Immunodeficiency.\nStudy: A Study A
 bout the Long-Term Safety of TAK-881 in People With Primary Immunodeficien
 cy Diseases\nEstimated primary completion: 16 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tak-881#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06076642
URL:https://assetmemo.bio/drug/tak-881#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100289-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06100289)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or
  Crohn's Disease\nEstimated primary completion: 16 May 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06100289
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747351-11365@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280625
DTEND;VALUE=DATE:20280626
SUMMARY:TAK-881: Phase 3 readout est. (NCT06747351)
DESCRIPTION:TAK-881\, phase 3.\nStudy: A Study to Compare TAK-881 and HYQVI
 A in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  (CIDP)\nEstimated primary completion: 25 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tak-881#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06747351
URL:https://assetmemo.bio/drug/tak-881#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07319845-11364@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Elritercept: Phase 2 readout est. (NCT07319845)
DESCRIPTION:Elritercept\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodyspla
 stic Syndromes\nEstimated primary completion: 26 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07319845
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196501-810@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Osavampator: Phase 3 readout est. (NCT07196501)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Tre
 atment in Participants With Major Depressive Disorder (MDD)\nEstimated pri
 mary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/osavampator#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07196501
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765602-10912@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:rusfertide: Phase 2 readout est. (NCT07765602)
DESCRIPTION:rusfertide\, phase 2\, Polycythemia Vera.\nStudy: A Study of Ru
 sfertide in Adults With Polycythemia Vera in China\nEstimated primary comp
 letion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rusfertide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07765602
URL:https://assetmemo.bio/drug/rusfertide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06165341-10767@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280826
DTEND;VALUE=DATE:20280827
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT06165341)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 Study to Learn About the Safety of Fazirsiran and if it Can Help People Wi
 th Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)\n
 Estimated primary completion: 26 August 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fazirsiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06165341
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463028-9075@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sapanisertib: Phase 2 readout est. (NCT06463028)
DESCRIPTION:Sapanisertib\, phase 2.\nStudy: Sapanisertib and Serabelisib (P
 IKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in 
 Patients With Advanced/Recurrent Endometrial Cancer\nEstimated primary com
 pletion: September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sapanisertib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06463028
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963827-3188@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280907
DTEND;VALUE=DATE:20280908
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06963827)
DESCRIPTION:Mezagitamab\, phase 3\, Chronic Kidney Disease.\nStudy: A Study
  of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy\nEs
 timated primary completion: 7 September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/mezagitamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963827
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06499285-11364@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Elritercept: Phase 3 readout est. (NCT06499285)
DESCRIPTION:Elritercept\, phase 3\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Elritercept to Treat Anemia in Adults With Very Low\, Low\, or Inte
 rmediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Trans
 fusions\nEstimated primary completion: 15 September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06499285
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081920-2254@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281019
DTEND;VALUE=DATE:20281020
SUMMARY:IBI363: Phase 2 readout est. (NCT06081920)
DESCRIPTION:IBI363\, phase 2.\nStudy: A Study of IBI363 in Subjects With Ad
 vanced Melanoma\nEstimated primary completion: 19 October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06081920
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722494-2254@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:IBI363: Phase 3 readout est. (NCT07722494)
DESCRIPTION:IBI363\, phase 3\, Colorectal Cancer.\nStudy: IBI363 Combined W
 ith Bevacizumab for Advanced Colorectal Cancer\nEstimated primary completi
 on: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ibi363#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07722494
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217301-2254@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:IBI363: Phase 3 readout est. (NCT07217301)
DESCRIPTION:IBI363\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
 \nEstimated primary completion: 1 November 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07217301
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205718-11367@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20281226
DTEND;VALUE=DATE:20281227
SUMMARY:TAK-188: Phase 1/2 readout est. (NCT07205718)
DESCRIPTION:TAK-188\, phase 1/2.\nStudy: A Study of TAK-188 in Adults With 
 Advanced or Spreading Solid Tumors\nEstimated primary completion: 26 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tak-188#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720571
 8
URL:https://assetmemo.bio/drug/tak-188#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059845-11140@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07059
 845)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Adverse Events and Change in Disease Activity o
 f Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansi
 ne in Adult Participants With Ovarian Cancer\nEstimated primary completion
 : January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirve
 tuximab-soravtansine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07059845
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06584032-2237@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0658403
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Endometrial Cance
 r.\nStudy: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced
  Endometrial Cancer\nEstimated primary completion: 8 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06584032
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823127-10897@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Livmarli (maralixibat): Phase 2 readout est. (NCT07823127)
DESCRIPTION:Livmarli (maralixibat)\, phase 2.\nStudy: MRX-901: An Open-labe
 l Study to Assess Safety and Tolerability of Maralixibat in Participants W
 ith Intrahepatic Cholestasis of Pregnancy (ICP)\nEstimated primary complet
 ion: 12 January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /maralixibat#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07823127
URL:https://assetmemo.bio/drug/maralixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613359-3188@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Mezagitamab: Phase 2 readout est. (NCT07613359)
DESCRIPTION:Mezagitamab\, phase 2.\nStudy: A Study of Mezagitamab in Adults
  With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant\nEs
 timated primary completion: 15 January 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/mezagitamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07613359
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05677971-10767@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290117
DTEND;VALUE=DATE:20290118
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT05677971)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help P
 eople With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Versio
 n of Alpha-1 Antitrypsin Protein\nEstimated primary completion: 17 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fazirsiran#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0567797
 1
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422480-11364@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Elritercept: Phase 3 readout est. (NCT07422480)
DESCRIPTION:Elritercept\, phase 3\, Myelodysplastic Syndromes.\nStudy: A St
 udy to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults Wit
 h Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Tra
 nsfusions\nEstimated primary completion: 30 April 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07422480
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558733-9075@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Sapanisertib: Phase 1/2 readout est. (NCT07558733)
DESCRIPTION:Sapanisertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in P
 atients With HR+/HER2- Advanced/Metastatic Breast Cancer\nEstimated primar
 y completion: May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sapanisertib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07558733
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966401-810@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Osavampator: Phase 3 readout est. (NCT06966401)
DESCRIPTION:Osavampator\, phase 3\, Major Depressive Disorder.\nStudy: Long
 -Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adj
 unctive Treatment in Participants With Major Depressive Disorder (MDD)\nEs
 timated primary completion: May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/osavampator#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06966401
URL:https://assetmemo.bio/drug/osavampator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948318-3188@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290729
DTEND;VALUE=DATE:20290730
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06948318)
DESCRIPTION:Mezagitamab\, phase 3.\nStudy: A Follow-up Study of Mezagitamab
  in Adults With Chronic Primary Immune Thrombocytopenia\nEstimated primary
  completion: 29 July 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/mezagitamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06948318
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550076-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290805
DTEND;VALUE=DATE:20290806
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06550076)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Study of TAK-279 i
 n Participants With Moderate-to-Severe Plaque Psoriasis\nEstimated primary
  completion: 5 August 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06550076
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204314-845@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trintellix (Vortioxetine): Phase 3 readout est. (NCT07204314)
DESCRIPTION:Trintellix (Vortioxetine)\, phase 3\, Major Depressive Disorder
 .\nStudy: A Study of Vortioxetine in Japanese Pediatric Patients With Majo
 r Depressive Disorder\nEstimated primary completion: 30 September 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vortioxetine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07204314
URL:https://assetmemo.bio/drug/vortioxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04419649-11364@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Elritercept: Phase 2 readout est. (NCT04419649)
DESCRIPTION:Elritercept\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Elritercept to Treat Anemia in Adults With Very Low\, Low\, or Inte
 rmediate Risk Myelodysplastic Syndromes (MDS)\nEstimated primary completio
 n: 30 October 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 lritercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04419649
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623161-11364@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20291207
DTEND;VALUE=DATE:20291208
SUMMARY:Elritercept: Phase 3 readout est. (NCT07623161)
DESCRIPTION:Elritercept\, phase 3.\nStudy: A Study to Compare Elritercept t
 o Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitin
 ib\nEstimated primary completion: 7 December 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07623161
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286058-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07286058)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: Continuati
 on Study of Zasocitinib in Adults With Psoriatic Arthritis\nEstimated prim
 ary completion: 18 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07286058
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764615-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:zasocitinib: Phase 2 readout est. (NCT06764615)
DESCRIPTION:zasocitinib\, phase 2.\nStudy: A Continuation Study of TAK-279 
 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)\nEstimated
  primary completion: 30 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06764615
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06443502-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06443502)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3.\nStudy: A Study to Learn About
  the Safety of Vedolizumab and How Well it Works in Children and Teenagers
  With Active Chronic Pouchitis\nEstimated primary completion: 31 January 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/vedolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06443502
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890338-11140@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06890
 338)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infus
 ed Carboplatin With Mirvetuximab Soravtansine in Participants With Newly D
 iagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epit
 helial Ovarian\, Fallopian Tube or Primary Peritoneal Cancer.\nEstimated p
 rimary completion: February 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/mirvetuximab-soravtansine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06890338
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05837897-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300308
DTEND;VALUE=DATE:20300309
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT05837897)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Crohn's Disease.\nStudy: A St
 udy of Vedolizumab in Adult Participants With Moderate to Severe Crohn's D
 isease\nEstimated primary completion: 8 March 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05837897
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871721-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300418
DTEND;VALUE=DATE:20300419
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07871721)
DESCRIPTION:zasocitinib\, phase 3\, Psoriatic Arthritis.\nStudy: A Study of
  Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)\nEstim
 ated primary completion: 18 April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/zasocitinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07871721
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-2031@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cabozantinib: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Cabozantinib\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long
 -Term Extension Study for Participants Previously Enrolled in an Exelixis-
 Sponsored Study\nEstimated primary completion: 31 May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06405087-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300812
DTEND;VALUE=DATE:20300813
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT06405087)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Long-Term Extension Study of Vedolizumab in Children and Teenagers With U
 lcerative Colitis (UC) or Crohn's Disease (CD)\nEstimated primary completi
 on: 12 August 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 edolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06405087
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436728-11368@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20300818
DTEND;VALUE=DATE:20300819
SUMMARY:TAK-505: Phase 1/2 readout est. (NCT07436728)
DESCRIPTION:TAK-505\, phase 1/2.\nStudy: A Study of TAK-505 in Adults With 
 Solid Tumors\nEstimated primary completion: 18 August 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tak-505#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07436728
URL:https://assetmemo.bio/drug/tak-505#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646678-11361@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20310615
DTEND;VALUE=DATE:20310616
SUMMARY:TAK-360: Phase 2/3 readout est. (NCT07646678)
DESCRIPTION:TAK-360\, phase 2/3\, Narcolepsy.\nStudy: A Study of TAK-360 in
  People With Narcolepsy or Idiopathic Hypersomnia\nEstimated primary compl
 etion: 15 June 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tak-360#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07646678
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05442567-7@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20330207
DTEND;VALUE=DATE:20330208
SUMMARY:Entyvio (vedolizumab): Phase 3 readout est. (NCT05442567)
DESCRIPTION:Entyvio (vedolizumab)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's 
 Disease (CD)\nEstimated primary completion: 7 February 2033. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vedolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05442567
URL:https://assetmemo.bio/drug/vedolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05899673-10767@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20330502
DTEND;VALUE=DATE:20330503
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT05899673)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 An Extension Study to Learn About the Long-Term Safety of Fazirsiran and i
 f Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease\nEstim
 ated primary completion: 2 May 2033. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fazirsiran#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05899673
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07250802-101@assetmemo.bio
DTSTAMP:20261121T005032Z
DTSTART;VALUE=DATE:20340703
DTEND;VALUE=DATE:20340704
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07250802)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Long-Term Study of
  Zasocitinib in Children and Teenagers With Plaque Psoriasis\nEstimated pr
 imary completion: 3 July 2034. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07250802
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
